34 / 35
NGS-based diagnostic assays
challenges
•
NGS panels are preferred over multiple
single assays (
(
Lindeman N. et al, JTO
2018)
•
Comprehensive vs. tailored NGS
approach.
•
Variety of different technologies
•
List of actionable mutations is
constantly growing.
•
“Liquid biopsy”: ready for prime
time? (Merker J. et al, JCO 2018)
•
Implementation challenges
•
Resources for the proper
interpretation: Tumour molecular
board
•
Turnaround time
•
Geographical accessibility
•
Access to clinical trials
Hierro C et al. Clin Cancer Res 2019